James K Stoller1,2, Loutfi S Aboussouan1, Richard E Kanner3, Laura A Wilson4, Phil Diaz5, Robert Wise6. 1. 1 Respiratory Institute, and. 2. 2 Education Institute, Cleveland Clinic, Cleveland, Ohio. 3. 3 Division of Pulmonary Medicine, University of Utah, Salt Lake City, Utah. 4. 4 Epedemiology Department, Johns Hopkins School of Public Health, Baltimore, Maryland. 5. 5 Pulmonary, Allergy, Critical Care, and Sleep Medicine Division, Ohio State University, Columbus, Ohio. 6. 6 Pulmonary and Critical Care Medicine, John Hopkins, Baltimore, Maryland; and.
Abstract
RATIONALE: Alpha-1 antitrypsin deficiency (AATD) predisposes to chronic obstructive pulmonary disease, but is underrecognized. Oxygenation and exercise desaturation in individuals with AATD-associated chronic obstructive pulmonary disease has been sparsely studied. The Long-term Oxygen Treatment Trial (LOTT) permits comparing these features of individuals with AATD with alpha-1 antitrypsin-replete (called "usual chronic obstructive pulmonary disease") LOTT participants. OBJECTIVES: Compare demographic, clinical, baseline oxygenation, and exercise desaturation features in participating AATD subjects with those of other LOTT subjects. METHODS: LOTT is a multicenter randomized controlled trial comparing use of supplemental oxygen versus not in subjects with chronic obstructive pulmonary disease and moderate hypoxemia (resting oxygen saturation as measured by pulse oximetry, 89-93%) ornormal oxygen saturation at rest and significant exercise desaturation. MEASUREMENT AND MAIN RESULTS: Among the 597 LOTT participants with nonmissing alpha-1 antitrypsin levels, 11 (1.8%) had severe AATD and 44 (7.4%) had mild/moderate AATD. Comparison of the 11 severely AAT-deficient individuals with the 542 LOTT participants with usual chronic obstructive pulmonary disease showed that the AATD subjects were younger and despite less smoking, had lower FEV1/FVC (mean post-bronchodilator FEV1/FVC, 0.38 ± 0.06 vs. 0.46 ± 0.13; P = 0.002). Comparison with 27 age-, sex-, and FEV1-matched alpha-1 antitrypsin-normal LOTT participants showed no baseline difference in resting room air pulse oximetry saturation (AATD, 93.6% ± 2.3% vs. 92.7% ± 2.2%; P = 0.64). Exercise-related desaturation was more severe in the individuals with AATD based on desaturation to 88% or less sooner during a 6-minute-walk test, having a higher percentage of desaturation points (e.g., <90%) during exercise, and having a higher distance-saturation product (defined as the distance walked in 6 min multiplied by the nadir saturation achieved during the 6-minute-walk test). CONCLUSIONS: These data suggest that individuals with AATD experience more profound desaturation with exercise than age-, sex-, race-, and FEV1-matched control subjects with usual chronic obstructive pulmonary disease. Clinical trial registered with www.clinicaltrials.gov (NCT 00692198).
RCT Entities:
RATIONALE: Alpha-1 antitrypsin deficiency (AATD) predisposes to chronic obstructive pulmonary disease, but is underrecognized. Oxygenation and exercise desaturation in individuals with AATD-associated chronic obstructive pulmonary disease has been sparsely studied. The Long-term Oxygen Treatment Trial (LOTT) permits comparing these features of individuals with AATD with alpha-1 antitrypsin-replete (called "usual chronic obstructive pulmonary disease") LOTT participants. OBJECTIVES: Compare demographic, clinical, baseline oxygenation, and exercise desaturation features in participating AATD subjects with those of other LOTT subjects. METHODS: LOTT is a multicenter randomized controlled trial comparing use of supplemental oxygen versus not in subjects with chronic obstructive pulmonary disease and moderate hypoxemia (resting oxygen saturation as measured by pulse oximetry, 89-93%) or normal oxygen saturation at rest and significant exercise desaturation. MEASUREMENT AND MAIN RESULTS: Among the 597 LOTT participants with nonmissing alpha-1 antitrypsin levels, 11 (1.8%) had severe AATD and 44 (7.4%) had mild/moderate AATD. Comparison of the 11 severely AAT-deficient individuals with the 542 LOTT participants with usual chronic obstructive pulmonary disease showed that the AATD subjects were younger and despite less smoking, had lower FEV1/FVC (mean post-bronchodilator FEV1/FVC, 0.38 ± 0.06 vs. 0.46 ± 0.13; P = 0.002). Comparison with 27 age-, sex-, and FEV1-matched alpha-1 antitrypsin-normal LOTT participants showed no baseline difference in resting room air pulse oximetry saturation (AATD, 93.6% ± 2.3% vs. 92.7% ± 2.2%; P = 0.64). Exercise-related desaturation was more severe in the individuals with AATD based on desaturation to 88% or less sooner during a 6-minute-walk test, having a higher percentage of desaturation points (e.g., <90%) during exercise, and having a higher distance-saturation product (defined as the distance walked in 6 min multiplied by the nadir saturation achieved during the 6-minute-walk test). CONCLUSIONS: These data suggest that individuals with AATD experience more profound desaturation with exercise than age-, sex-, race-, and FEV1-matched control subjects with usual chronic obstructive pulmonary disease. Clinical trial registered with www.clinicaltrials.gov (NCT 00692198).
Authors: M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger Journal: Eur Respir J Date: 2005-08 Impact factor: 16.671
Authors: N G McElvaney; J K Stoller; A S Buist; U B Prakash; M L Brantly; M D Schluchter; R D Crystal Journal: Chest Date: 1997-02 Impact factor: 9.410
Authors: Roger D Yusen; Gerard J Criner; Alice L Sternberg; David H Au; Anne L Fuhlbrigge; Richard K Albert; Richard Casaburi; James K Stoller; Kathleen F Harrington; J Allen D Cooper; Philip Diaz; Steven Gay; Richard Kanner; Neil MacIntyre; Fernando J Martinez; Steven Piantadosi; Frank Sciurba; David Shade; Thomas Stibolt; James Tonascia; Robert Wise; William C Bailey Journal: Ann Am Thorac Soc Date: 2018-01
Authors: Florian M Karl; Rolf Holle; Robert Bals; Timm Greulich; Rudolf A Jörres; Annika Karch; Armin Koch; Stefan Karrasch; Reiner Leidl; Holger Schulz; Claus Vogelmeier; Margarethe E Wacker Journal: Respir Res Date: 2017-04-17
Authors: Robert Sandhaus; Charlie Strange; Glenda Stone; M Chris Runken; Christopher M Blanchette; Reuben Howden Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-10-05